When to cut when not to cut 🗡️ can some bladders be saved and answer is yes with right biomarkers combining utDNA and ctDNA to risk stratify to surveillance surgery vs more systemic therapy nicely summarized by @BenjaminPradere#SMU26 read @EUplatinum editorial supporting this as well sciencedirect.com/science/ar…
JUST IN: @AmericanCancer (ACS) updates their guidance about routine PSA screening for #prostatecancer, moving off "shared decision-making".
This is a major shift since the last ACS recommendations in 2010:
1) High risk (Black men; first-degree relative dx <65 or multiple at any age): annual PSA, ages 45-69
2) Average risk: PSA every 2 years, ages 50–69. American Cancer Society
3) Non-Black men with 1 first-degree relative diagnosed ≥65: PSA every 2 years, ages 45–69.
4) Age 70–74: individualized decision; if screening continues, every 2 years.
5) Age ≥75: generally no screening; very healthy men 75–79 may discuss continued screening.
6) No screening ≥80 and no screening at any age with life expectancy <10 years.
@CACancerJournal@DanaFarber_GU@harvardmed@OpenMedInsights
Link: acsjournals.onlinelibrary.wi…
🚨 Major shift: @AmericanCancer now directly recommends routine PSA screening for #prostatecancer, moving off pure shared decision-making 🚨
@CACancerJournal
📋 Average risk: PSA every 2 yrs, ages 50-69
📋 High risk (Black men; first-degree relative dx <65 or multiple at any age): annual PSA, ages 45-69
📋 Non-Black w/ one first-degree relative dx ≥65: every 2 yrs, ages 45-69
🔬 Age-adjusted elevated = PSA ≥3.0 (ages 45-69) or ≥6.5 (70-74); repeat in 2 wks to 3 mo, then MRI and/or validated biomarker before biopsy
🛑 70-74 individualized; not recommended ≥75 or if life expectancy <10 yrs
⚠️ Still requires informed consent on benefits, limits, and harms, and departs from USPSTF’s grade C for 55-69
🎯 ACS has moved from “discuss it” to “do it” for average-risk men 50-69 and high-risk men from 45, its biggest change since 2010
🔗 doi.org/10.3322/caac.70112@UroOnc@urotoday@UrologyTimes@PCF_Science@AmerUrological
Medical students, residents, and clinical researchers rejoice—we present the beginning of the end for manual chart review.
doi.org/10.1038/s41746-026-0…
Our locally deployed LLM extracted 136,425 data points from 130K clinical notes with 97.5% agreement—outperforming manual review
Grateful to attend the @FocalSociety’s @UroOnc course for the next couple days! So much great learning from giants in the field. Great to be back in Cleveland with old friends and colleagues as well 🥰
With VOLGA results coming at #ESMO26, a summary of contemporary phase III perioperative trials in muscle-invasive bladder cancer.
⚠️ Different populations and designs—avoid cross-trial comparisons. VOLGA and EV-303 importantly include surgery-alone control arms without neoadjuvant therapy.
🔑 The next challenge: identifying who truly needs adjuvant ADC therapy—and who can safely avoid it.
#BladderCancer#GUOnc@OncoAlert@BladderCancerUS
Original Article: Durvalumab, Tremelimumab, and Enfortumab Vedotin in Muscle-Invasive Bladder Cancer (phase 3 VOLGA trial) nej.md/4z7dQFm#ESMO26 | @myESMO
PROTEUS Substudy: Periop Apa + ADT with RP+PLND vs RP+PLND in HR PCa @urotoday#ESMO26
Periop APA + ADT (+ RP+PLND; n= 102) vs RP+PLND alone (n=306)
🚨EFS: HR 0.38, 95% CI 0.26–0.55
🚨MFS: HR 0.49, 95% CI 0.26–0.90
🚨TT 1st Sub Rx: HR 0.29, 95% CI 0.20–0.43
🚨All Gr Hot Flush: 64% vs 0.7%
It has been nearly 5 months since the FDA approved durvalumab + BCG for “BCG-naïve” high-risk #NMIBC based on the POTOMAC trial.
There has been considerable discussion about the discordant results of the recent phase III trials evaluating BCG + immune checkpoint blockade.
But I think we're overlooking a potentially important difference between these trials, one that could have major implications for how we interpret the results and counsel our patients.
POTOMAC and CREST were positive trials, but unlike the negative ALBAN trial, both permitted enrollment of patients previously treated with BCG.
To my knowledge, neither has reported how many patients had prior BCG exposure or whether the benefit of adding checkpoint blockade differs between previously treated and truly BCG-naïve patients.
Given the additional toxicity, treatment burden, and cost of systemic checkpoint blockade, how can we adequately counsel patients receiving BCG for the first time without knowing the magnitude of benefit specifically in patients like them?
I think we need to see these subgroup data from @AstraZeneca and @pfizer .
1/n
@BladderCancerUS ; @BCAN_Research ; @SUO_YUO ; @UroOnc ; @FDA ; @chana_weinstock ; @AmerUrological
This is a paper everyone needs to read .. it may ( with time and validation) change our field significantly in both NMIBC and MIBC management couple 💭
- HUGE benefit of cfRNA is 0️⃣dependence on tissue .. anyone trying to do utdna on Ta/ small focus HG/ CIS knows how valuable this is but utDNA tumor informed=cfRNA
- bcg prediction is immature and underpowered but strong signal
- ❗️consider false positives in here 11% in noncancer ctrl. Promising results nonetheless and better than anything we have out there ..
- no validation / testing post tmt the most difficult cohort for surveillance with urine based testing and that is why we @CleClinicUro are excited to partner with @max_diehn and ReseroBio to continue their validation
When "cancer" is a diagnosis but not really a disease
A slightly more philosophical piece than my usual—on what we mean by cancer, and whether the word itself can sometimes do more harm than good.... let me know what you think!
Many thanks @pam3001@aeonmagaeon.co/essays/we-need-a-bet…
Your patient has had nephrectomy for high-risk clear cell RCC. The next decision: Surveillance, Pembrolizumab, or Pembrolizumab + belzutifan. Is adjuvant justified when surgery may already have been curative? Our new commentary explores this dilemma. 🧵bit.ly/4jkism6